190 related articles for article (PubMed ID: 10202232)
1. Levofloxacin in the treatment of community acquired pneumonia.
File TM
Can Respir J; 1999; 6 Suppl A():35A-9A. PubMed ID: 10202232
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
[TBL] [Abstract][Full Text] [Related]
3. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
[TBL] [Abstract][Full Text] [Related]
4. The use of levofloxacin in the treatment of respiratory tract infection.
Shah PM
J Chemother; 2000 Oct; 12 Suppl 4():27-31. PubMed ID: 11131957
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
6. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
Rittenhouse BE; Stinnett AA; Dulisse B; Henke CJ; Potter L; Parasuraman B; Martens LL; Williams RR; Kojak C
Am J Manag Care; 2000 Mar; 6(3):381-9. PubMed ID: 10977438
[TBL] [Abstract][Full Text] [Related]
8. Oral levofloxacin in the treatment of community-acquired pneumonia.
Nicodemo AC; Lima Nicodemo E; Idrahim KY
Braz J Infect Dis; 2000 Apr; 4(2):61-6. PubMed ID: 10795070
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.
Davies BI; Maesen FP
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():83-90. PubMed ID: 10404344
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
Croom KF; Goa KL
Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
[TBL] [Abstract][Full Text] [Related]
11. [Levofloxacin in the treatment of community-acquired pneumococcal pneumonia].
Léophonte P; Veyssier P
Presse Med; 1999 Nov; 28(36):1975-9. PubMed ID: 10599260
[TBL] [Abstract][Full Text] [Related]
12. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Hammerschlag MR; Roblin PM
Antimicrob Agents Chemother; 2000 May; 44(5):1409. PubMed ID: 10819727
[No Abstract] [Full Text] [Related]
13. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
Langtry HD; Lamb HM
Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
[TBL] [Abstract][Full Text] [Related]
14. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
16. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
Scheen AJ
Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
Fogarty CM; Greenberg RN; Dunbar L; Player R; Marrie TJ; Kojak CM; Morgan N; Williams RR
Clin Ther; 2001 Mar; 23(3):425-39. PubMed ID: 11318077
[TBL] [Abstract][Full Text] [Related]
20. New insights in the treatment by levofloxacin.
File TM
Chemotherapy; 2004; 50 Suppl 1():22-8. PubMed ID: 15319551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
